Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study

We investigated the efficacy of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes for 4 years in clinical practice. Between 2009 and 2010, we reviewed 1,178 patients with type 2 diabetes (HbA1c ≥7.5% or 58 mmol/mol) prescribed initial combination therapy wit...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-06, Vol.10 (6), p.e0129477
Main Authors: Ku, Eu Jeong, Jung, Kyong Yeon, Kim, Yoon Ji, Kim, Kyoung Min, Moon, Jae Hoon, Choi, Sung Hee, Cho, Young Min, Park, Kyong Soo, Jang, Hak Chul, Lim, Soo, Ahrén, Bo
Format: Article
Language:English
Subjects:
Adult
Aged
Alcohol use
Annan klinisk medicin
Antidiabetics
Body mass
Care and treatment
Clinical Medicine
Combination therapy
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Drug Therapy, Combination
Durability
Endocrinology and Diabetes
Endokrinologi och diabetes
FDA approval
Female
Glucose
Hemoglobin
Hemoglobin A - metabolism
Homeostasis
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Insulin
Insulin resistance
Internal medicine
Klinisk medicin
Male
Medical and Health Sciences
Medical research
Medicin och hälsovetenskap
Medicine
Metformin
Metformin - administration & dosage
Metformin - adverse effects
Metformin - therapeutic use
Middle Aged
Other Clinical Medicine
Patients
Reduction
Review boards
Sitagliptin Phosphate - administration & dosage
Sitagliptin Phosphate - adverse effects
Sitagliptin Phosphate - therapeutic use
Studies
Systematic review
Therapy
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c761t-979b820b95f0cedf1295d5bb2e817a372c830ec044de2adb717e09d1cd5cbc0b3
cites cdi_FETCH-LOGICAL-c761t-979b820b95f0cedf1295d5bb2e817a372c830ec044de2adb717e09d1cd5cbc0b3
container_end_page
container_issue 6
container_start_page e0129477
container_title PloS one
container_volume 10
creator Ku, Eu Jeong
Jung, Kyong Yeon
Kim, Yoon Ji
Kim, Kyoung Min
Moon, Jae Hoon
Choi, Sung Hee
Cho, Young Min
Park, Kyong Soo
Jang, Hak Chul
Lim, Soo
Ahrén, Bo
description We investigated the efficacy of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes for 4 years in clinical practice. Between 2009 and 2010, we reviewed 1,178 patients with type 2 diabetes (HbA1c ≥7.5% or 58 mmol/mol) prescribed initial combination therapy with sitagliptin and metformin. After excluding 288 patients without a second follow-up, 890 individuals (age, 58.0 ± 12.5 years; BMI, 25.4 ± 3.5 kg/m2; HbA1c, 8.6 ± 1.1%) were followed up with every 3-6 months for 4 years. Homeostasis model assessments for insulin resistance and β-cell function (HOMA-β) were recorded at baseline. The response criterion was HbA1c reduction by ≥0.8% from baseline or attainment of the target HbA1c (≤7.0% or 53 mmol/mol). At the end of every year of treatment, changes in HbA1c from the baseline were assessed. After 1 year, 72.2% of patients with initial combination therapy had responded, defined as HbA1c reduction ≥0.8% or attainment of the target HbA1c ≤7.0%. After 4 years, 35.4% of the patients still showed a response, with an HbA1c level of 7.0 ± 0.9%. A high HbA1c level at baseline was the most significant independent predictor of the long-term response (P
doi_str_mv 10.1371/journal.pone.0129477
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1687821797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A417656787</galeid><doaj_id>oai_doaj_org_article_06c4e80916004ea39f40ab1a22afa7bc</doaj_id><sourcerecordid>A417656787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c761t-979b820b95f0cedf1295d5bb2e817a372c830ec044de2adb717e09d1cd5cbc0b3</originalsourceid><addsrcrecordid>eNqNk39r1DAYx4sobk7fgWhBEPzjziT9kQZBGDenBxsb3hT8KzxJn95l9JqapM57I75ec95trKAgbWiafp4PzZc8SfKckinNOH17bQfXQTvtbYdTQpnIOX-QHFKRsUnJSPbw3vwgeeL9NSFFVpXl4-SAlaSMM3qY_DqNmsk3BJeeDA6UaU3YpLZJ550JBtp0ZtfKdBCM7dKrFTroN-mNCat0YQIsW9MH06XQ1ek5hsa6dXyL92UswC74HXq16TFl6YkBhQH9Fpi1pjM6-i8d6GA0vktnF4vz-SxdhKHePE0eNdB6fLZ_HiVfTj9czT5Nzi4-zmfHZxPNSxomggtVMaJE0RCNdRNTKOpCKYYV5ZBxpquMoCZ5XiODWnHKkYia6rrQShOVHSUvd96-tV7uI_WSlhWvGOWCR2K-I2oL17J3Zg1uIy0Y-WfBuqUEFzfQoiSlzrEigpaE5AiZaHICigJj0ABXOrrOdi5_g_2gRrZ26ONQcUiPMueCFaKgkhYgZK6qWoqCoOS8IllBG1VlEHXv9z8_qDXWOgbuoB1Zx186s5JL-0PmeVkWUXSUvNoLnP0-oA__SGBPLSFu0nSNjTK9Nl7L45zysih5taWmf6HiVePa6HhGGxPXRwVvRgWRCfgzLGHwXs4Xn_-fvfg6Zl_fY1cIbVh52w7bE-zHYL4DtbPeO2zukqNEblvsNg25bTG5b7FY9uJ-6ndFtz2V_QZvtyH5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687821797</pqid></control><display><type>article</type><title>Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Ku, Eu Jeong ; Jung, Kyong Yeon ; Kim, Yoon Ji ; Kim, Kyoung Min ; Moon, Jae Hoon ; Choi, Sung Hee ; Cho, Young Min ; Park, Kyong Soo ; Jang, Hak Chul ; Lim, Soo ; Ahrén, Bo</creator><contributor>Sesti, Giorgio</contributor><creatorcontrib>Ku, Eu Jeong ; Jung, Kyong Yeon ; Kim, Yoon Ji ; Kim, Kyoung Min ; Moon, Jae Hoon ; Choi, Sung Hee ; Cho, Young Min ; Park, Kyong Soo ; Jang, Hak Chul ; Lim, Soo ; Ahrén, Bo ; Sesti, Giorgio</creatorcontrib><description>We investigated the efficacy of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes for 4 years in clinical practice. Between 2009 and 2010, we reviewed 1,178 patients with type 2 diabetes (HbA1c ≥7.5% or 58 mmol/mol) prescribed initial combination therapy with sitagliptin and metformin. After excluding 288 patients without a second follow-up, 890 individuals (age, 58.0 ± 12.5 years; BMI, 25.4 ± 3.5 kg/m2; HbA1c, 8.6 ± 1.1%) were followed up with every 3-6 months for 4 years. Homeostasis model assessments for insulin resistance and β-cell function (HOMA-β) were recorded at baseline. The response criterion was HbA1c reduction by ≥0.8% from baseline or attainment of the target HbA1c (≤7.0% or 53 mmol/mol). At the end of every year of treatment, changes in HbA1c from the baseline were assessed. After 1 year, 72.2% of patients with initial combination therapy had responded, defined as HbA1c reduction ≥0.8% or attainment of the target HbA1c ≤7.0%. After 4 years, 35.4% of the patients still showed a response, with an HbA1c level of 7.0 ± 0.9%. A high HbA1c level at baseline was the most significant independent predictor of the long-term response (P&lt;0.001). In addition, low HOMA-β was a significant predictor of a greater reduction in HbA1c. This treatment was generally well tolerated over the 4-year follow-up period, without any serious adverse events. This real-world follow-up study shows a persistent glucose-reducing effect of initial combination therapy with sitagliptin and metformin for up to 4 years.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0129477</identifier><identifier>PMID: 26068661</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Aged ; Alcohol use ; Annan klinisk medicin ; Antidiabetics ; Body mass ; Care and treatment ; Clinical Medicine ; Combination therapy ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Drug Therapy, Combination ; Durability ; Endocrinology and Diabetes ; Endokrinologi och diabetes ; FDA approval ; Female ; Glucose ; Hemoglobin ; Hemoglobin A - metabolism ; Homeostasis ; Humans ; Hypoglycemic Agents - administration &amp; dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin resistance ; Internal medicine ; Klinisk medicin ; Male ; Medical and Health Sciences ; Medical research ; Medicin och hälsovetenskap ; Medicine ; Metformin ; Metformin - administration &amp; dosage ; Metformin - adverse effects ; Metformin - therapeutic use ; Middle Aged ; Other Clinical Medicine ; Patients ; Reduction ; Review boards ; Sitagliptin Phosphate - administration &amp; dosage ; Sitagliptin Phosphate - adverse effects ; Sitagliptin Phosphate - therapeutic use ; Studies ; Systematic review ; Therapy ; Type 2 diabetes</subject><ispartof>PloS one, 2015-06, Vol.10 (6), p.e0129477</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Ku et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Ku et al 2015 Ku et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c761t-979b820b95f0cedf1295d5bb2e817a372c830ec044de2adb717e09d1cd5cbc0b3</citedby><cites>FETCH-LOGICAL-c761t-979b820b95f0cedf1295d5bb2e817a372c830ec044de2adb717e09d1cd5cbc0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1687821797/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1687821797?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26068661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/7486652$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>Sesti, Giorgio</contributor><creatorcontrib>Ku, Eu Jeong</creatorcontrib><creatorcontrib>Jung, Kyong Yeon</creatorcontrib><creatorcontrib>Kim, Yoon Ji</creatorcontrib><creatorcontrib>Kim, Kyoung Min</creatorcontrib><creatorcontrib>Moon, Jae Hoon</creatorcontrib><creatorcontrib>Choi, Sung Hee</creatorcontrib><creatorcontrib>Cho, Young Min</creatorcontrib><creatorcontrib>Park, Kyong Soo</creatorcontrib><creatorcontrib>Jang, Hak Chul</creatorcontrib><creatorcontrib>Lim, Soo</creatorcontrib><creatorcontrib>Ahrén, Bo</creatorcontrib><title>Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>We investigated the efficacy of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes for 4 years in clinical practice. Between 2009 and 2010, we reviewed 1,178 patients with type 2 diabetes (HbA1c ≥7.5% or 58 mmol/mol) prescribed initial combination therapy with sitagliptin and metformin. After excluding 288 patients without a second follow-up, 890 individuals (age, 58.0 ± 12.5 years; BMI, 25.4 ± 3.5 kg/m2; HbA1c, 8.6 ± 1.1%) were followed up with every 3-6 months for 4 years. Homeostasis model assessments for insulin resistance and β-cell function (HOMA-β) were recorded at baseline. The response criterion was HbA1c reduction by ≥0.8% from baseline or attainment of the target HbA1c (≤7.0% or 53 mmol/mol). At the end of every year of treatment, changes in HbA1c from the baseline were assessed. After 1 year, 72.2% of patients with initial combination therapy had responded, defined as HbA1c reduction ≥0.8% or attainment of the target HbA1c ≤7.0%. After 4 years, 35.4% of the patients still showed a response, with an HbA1c level of 7.0 ± 0.9%. A high HbA1c level at baseline was the most significant independent predictor of the long-term response (P&lt;0.001). In addition, low HOMA-β was a significant predictor of a greater reduction in HbA1c. This treatment was generally well tolerated over the 4-year follow-up period, without any serious adverse events. This real-world follow-up study shows a persistent glucose-reducing effect of initial combination therapy with sitagliptin and metformin for up to 4 years.</description><subject>Adult</subject><subject>Aged</subject><subject>Alcohol use</subject><subject>Annan klinisk medicin</subject><subject>Antidiabetics</subject><subject>Body mass</subject><subject>Care and treatment</subject><subject>Clinical Medicine</subject><subject>Combination therapy</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Durability</subject><subject>Endocrinology and Diabetes</subject><subject>Endokrinologi och diabetes</subject><subject>FDA approval</subject><subject>Female</subject><subject>Glucose</subject><subject>Hemoglobin</subject><subject>Hemoglobin A - metabolism</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration &amp; dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Internal medicine</subject><subject>Klinisk medicin</subject><subject>Male</subject><subject>Medical and Health Sciences</subject><subject>Medical research</subject><subject>Medicin och hälsovetenskap</subject><subject>Medicine</subject><subject>Metformin</subject><subject>Metformin - administration &amp; dosage</subject><subject>Metformin - adverse effects</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Other Clinical Medicine</subject><subject>Patients</subject><subject>Reduction</subject><subject>Review boards</subject><subject>Sitagliptin Phosphate - administration &amp; dosage</subject><subject>Sitagliptin Phosphate - adverse effects</subject><subject>Sitagliptin Phosphate - therapeutic use</subject><subject>Studies</subject><subject>Systematic review</subject><subject>Therapy</subject><subject>Type 2 diabetes</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk39r1DAYx4sobk7fgWhBEPzjziT9kQZBGDenBxsb3hT8KzxJn95l9JqapM57I75ec95trKAgbWiafp4PzZc8SfKckinNOH17bQfXQTvtbYdTQpnIOX-QHFKRsUnJSPbw3vwgeeL9NSFFVpXl4-SAlaSMM3qY_DqNmsk3BJeeDA6UaU3YpLZJ550JBtp0ZtfKdBCM7dKrFTroN-mNCat0YQIsW9MH06XQ1ek5hsa6dXyL92UswC74HXq16TFl6YkBhQH9Fpi1pjM6-i8d6GA0vktnF4vz-SxdhKHePE0eNdB6fLZ_HiVfTj9czT5Nzi4-zmfHZxPNSxomggtVMaJE0RCNdRNTKOpCKYYV5ZBxpquMoCZ5XiODWnHKkYia6rrQShOVHSUvd96-tV7uI_WSlhWvGOWCR2K-I2oL17J3Zg1uIy0Y-WfBuqUEFzfQoiSlzrEigpaE5AiZaHICigJj0ABXOrrOdi5_g_2gRrZ26ONQcUiPMueCFaKgkhYgZK6qWoqCoOS8IllBG1VlEHXv9z8_qDXWOgbuoB1Zx186s5JL-0PmeVkWUXSUvNoLnP0-oA__SGBPLSFu0nSNjTK9Nl7L45zysih5taWmf6HiVePa6HhGGxPXRwVvRgWRCfgzLGHwXs4Xn_-fvfg6Zl_fY1cIbVh52w7bE-zHYL4DtbPeO2zukqNEblvsNg25bTG5b7FY9uJ-6ndFtz2V_QZvtyH5</recordid><startdate>20150612</startdate><enddate>20150612</enddate><creator>Ku, Eu Jeong</creator><creator>Jung, Kyong Yeon</creator><creator>Kim, Yoon Ji</creator><creator>Kim, Kyoung Min</creator><creator>Moon, Jae Hoon</creator><creator>Choi, Sung Hee</creator><creator>Cho, Young Min</creator><creator>Park, Kyong Soo</creator><creator>Jang, Hak Chul</creator><creator>Lim, Soo</creator><creator>Ahrén, Bo</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AGCHP</scope><scope>AOWAS</scope><scope>D8T</scope><scope>D95</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>20150612</creationdate><title>Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study</title><author>Ku, Eu Jeong ; Jung, Kyong Yeon ; Kim, Yoon Ji ; Kim, Kyoung Min ; Moon, Jae Hoon ; Choi, Sung Hee ; Cho, Young Min ; Park, Kyong Soo ; Jang, Hak Chul ; Lim, Soo ; Ahrén, Bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c761t-979b820b95f0cedf1295d5bb2e817a372c830ec044de2adb717e09d1cd5cbc0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alcohol use</topic><topic>Annan klinisk medicin</topic><topic>Antidiabetics</topic><topic>Body mass</topic><topic>Care and treatment</topic><topic>Clinical Medicine</topic><topic>Combination therapy</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Durability</topic><topic>Endocrinology and Diabetes</topic><topic>Endokrinologi och diabetes</topic><topic>FDA approval</topic><topic>Female</topic><topic>Glucose</topic><topic>Hemoglobin</topic><topic>Hemoglobin A - metabolism</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration &amp; dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Internal medicine</topic><topic>Klinisk medicin</topic><topic>Male</topic><topic>Medical and Health Sciences</topic><topic>Medical research</topic><topic>Medicin och hälsovetenskap</topic><topic>Medicine</topic><topic>Metformin</topic><topic>Metformin - administration &amp; dosage</topic><topic>Metformin - adverse effects</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Other Clinical Medicine</topic><topic>Patients</topic><topic>Reduction</topic><topic>Review boards</topic><topic>Sitagliptin Phosphate - administration &amp; dosage</topic><topic>Sitagliptin Phosphate - adverse effects</topic><topic>Sitagliptin Phosphate - therapeutic use</topic><topic>Studies</topic><topic>Systematic review</topic><topic>Therapy</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ku, Eu Jeong</creatorcontrib><creatorcontrib>Jung, Kyong Yeon</creatorcontrib><creatorcontrib>Kim, Yoon Ji</creatorcontrib><creatorcontrib>Kim, Kyoung Min</creatorcontrib><creatorcontrib>Moon, Jae Hoon</creatorcontrib><creatorcontrib>Choi, Sung Hee</creatorcontrib><creatorcontrib>Cho, Young Min</creatorcontrib><creatorcontrib>Park, Kyong Soo</creatorcontrib><creatorcontrib>Jang, Hak Chul</creatorcontrib><creatorcontrib>Lim, Soo</creatorcontrib><creatorcontrib>Ahrén, Bo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SWEPUB Lunds universitet full text</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Lunds universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ku, Eu Jeong</au><au>Jung, Kyong Yeon</au><au>Kim, Yoon Ji</au><au>Kim, Kyoung Min</au><au>Moon, Jae Hoon</au><au>Choi, Sung Hee</au><au>Cho, Young Min</au><au>Park, Kyong Soo</au><au>Jang, Hak Chul</au><au>Lim, Soo</au><au>Ahrén, Bo</au><au>Sesti, Giorgio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-06-12</date><risdate>2015</risdate><volume>10</volume><issue>6</issue><spage>e0129477</spage><pages>e0129477-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>We investigated the efficacy of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes for 4 years in clinical practice. Between 2009 and 2010, we reviewed 1,178 patients with type 2 diabetes (HbA1c ≥7.5% or 58 mmol/mol) prescribed initial combination therapy with sitagliptin and metformin. After excluding 288 patients without a second follow-up, 890 individuals (age, 58.0 ± 12.5 years; BMI, 25.4 ± 3.5 kg/m2; HbA1c, 8.6 ± 1.1%) were followed up with every 3-6 months for 4 years. Homeostasis model assessments for insulin resistance and β-cell function (HOMA-β) were recorded at baseline. The response criterion was HbA1c reduction by ≥0.8% from baseline or attainment of the target HbA1c (≤7.0% or 53 mmol/mol). At the end of every year of treatment, changes in HbA1c from the baseline were assessed. After 1 year, 72.2% of patients with initial combination therapy had responded, defined as HbA1c reduction ≥0.8% or attainment of the target HbA1c ≤7.0%. After 4 years, 35.4% of the patients still showed a response, with an HbA1c level of 7.0 ± 0.9%. A high HbA1c level at baseline was the most significant independent predictor of the long-term response (P&lt;0.001). In addition, low HOMA-β was a significant predictor of a greater reduction in HbA1c. This treatment was generally well tolerated over the 4-year follow-up period, without any serious adverse events. This real-world follow-up study shows a persistent glucose-reducing effect of initial combination therapy with sitagliptin and metformin for up to 4 years.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26068661</pmid><doi>10.1371/journal.pone.0129477</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2015-06, Vol.10 (6), p.e0129477
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1687821797
source Publicly Available Content Database; PubMed Central(OpenAccess)
subjects Adult
Aged
Alcohol use
Annan klinisk medicin
Antidiabetics
Body mass
Care and treatment
Clinical Medicine
Combination therapy
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Drug Therapy, Combination
Durability
Endocrinology and Diabetes
Endokrinologi och diabetes
FDA approval
Female
Glucose
Hemoglobin
Hemoglobin A - metabolism
Homeostasis
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Insulin
Insulin resistance
Internal medicine
Klinisk medicin
Male
Medical and Health Sciences
Medical research
Medicin och hälsovetenskap
Medicine
Metformin
Metformin - administration & dosage
Metformin - adverse effects
Metformin - therapeutic use
Middle Aged
Other Clinical Medicine
Patients
Reduction
Review boards
Sitagliptin Phosphate - administration & dosage
Sitagliptin Phosphate - adverse effects
Sitagliptin Phosphate - therapeutic use
Studies
Systematic review
Therapy
Type 2 diabetes
title Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A56%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Four-Year%20Durability%20of%20Initial%20Combination%20Therapy%20with%20Sitagliptin%20and%20Metformin%20in%20Patients%20with%20Type%202%20Diabetes%20in%20Clinical%20Practice;%20COSMIC%20Study&rft.jtitle=PloS%20one&rft.au=Ku,%20Eu%20Jeong&rft.date=2015-06-12&rft.volume=10&rft.issue=6&rft.spage=e0129477&rft.pages=e0129477-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0129477&rft_dat=%3Cgale_plos_%3EA417656787%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c761t-979b820b95f0cedf1295d5bb2e817a372c830ec044de2adb717e09d1cd5cbc0b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1687821797&rft_id=info:pmid/26068661&rft_galeid=A417656787&rfr_iscdi=true